XNYS · Drug Manufacturers - Specialty & Generic
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$82.46+0.17%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
57/100
Positive
Score components
TickerWhale View
Zoetis Inc - scores 57 out of 100 overall, which we rate positive. Valuation is its strongest area and Sentiment Signal its weakest.
What helps
- Technical
- Quality & growth
- Valuation
What to watch
- Sentiment Signal
Quality & growth
30%62Positive
- Revenue growth 1.5%
- EPS growth 5.4%
Valuation
25%63Positive
- P/E 13.2
- EV/Sales 4.4
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
#320 by market cap in our coverage · ~14,500 employees · Listed 2013-02-01 · www.zoetis.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#64 / 139sector rank by TickerWhale Score
TickerWhale Score 57 vs sector average 54.6 (+2.4)
Revenue growth (industry)Top 100%
Gross margin (industry)Top 56%
Return on equity (industry)Top 29%
P/E (industry)Cheaper than 100%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
51/100Moderate vs universe
Ranks 51st of 100 covered names on our technical composite — the composite itself scores 57/100 · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
4 buy · 1 sell · 3 neutral of 8 votes
TickerWhale rates ZTS's technical setup middling — 51st percentile of the covered universe. Classic chart indicators lean buy — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
7 / 9constructive
- vs 200-day-10.4%
- vs 50-day+8.6%
Momentum
Mixed
- RSI (14)56 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength37· trending
- MACD (12,26,9)sell(histogram -0.035)
How the classic verdict is reached
Moving averages (9) agree on buy — 7 buy vs 2 sell — and carry one vote between them.
Oscillators (7) vote individually: 3 buy · 1 sell · 3 neutral.
Result — 4 buy vs 1 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)13.2
- P/S (TTM)3.6
- P/B10.9
- EV/EBITDA—
- EV/Sales4.4
- PEG2.45
Profitability & returns
- Gross margin71.5%
- Net margin27.5%
- ROE82.0%
- Debt/Equity2.87
Growth
- Revenue growth (YoY)1.5%
- EPS growth (YoY)5.4%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $34.4B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ZTSCurrentZoetis Inc - | 57 | 57 | 13.2 | — | 10.9 | 4.4 | $82.46 | +0.17% | +1.5% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.